IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of:

Docket No.: A8461

James E. Galen

Conf. No.: 5386

Appln. No.: 09/993,292

Group Art Unit: 1645

Filed: November 23, 2001

Examiner: Duffy, P.

For:

USE OF CLYA HEMOLYSIN FOR EXCRETION OF PROTEINS

STATEMENT TO SUPPORT FILING AND SUBMISSION IN **ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825**

MAIL STOP SEQUENCE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In connection with the substitute Sequence Listing submitted herewith, the undersigned hereby states that:

- the submission, filed herewith in accordance with 37 C.F.R. §1.821(g), does not include 1. any new matter;
- 2. the contents of the 32-page substitute Sequence Listing being filed in the present application, and the attached computer readable copy of the substitute Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same;
 - Applicant respectfully requests entry of the Sequence Listing into the application; and 3.
- 4. all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

CUSTOMER NUMBER

Drew Hissong

Registration No. 44,765

Respectfully submitted

Date: October 5, 2004